Atomoxetine cost-effective in ADHD
- PDF / 142,115 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 88 Downloads / 221 Views
ICER (£/QALY)
Stimulant-naive vs immediate-release methylphenidate 15 224 vs extended-release methylphenidate 13 241 Stimulant-failed (on methylphenidate) vs dexamfetamine 14 945 Stimulant-averse vs immediate-release methylphenidate 15 878 vs extended-release methylphenidate 14 169 Stimulant-contraindicated (drug-naive) vs no treatment 11 523 Stimulant-contraindicated (previously exposed to stimulant) vs no treatment 12 370
Results showed atomoxetine to be a cost-effective option across all ADHD population with incremental cost-effectiveness ratios (ICERs) ranging from £11 523 to £15 878 per QALY [see table]. The results were within acceptability limits for the UK and the rest of the Europe. The higher acquisition costs were compensated by the higher utility values achieved during treatment of ADHD with atomoxetine, compared with stimulants. Prasad S, et al. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK. International Journal of Clinical Practice 63: 801149521 1031-1040, No. 7, Jul 2009
1173-5503/10/0584-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 8 Aug 2009 No. 584
1
Data Loading...
